One significant AML subtype, acute promyelocytic leukemia (APL), M3-M3v/t(15;17)(q24;q21), now referred to as APL with PML-RARA, can be cured by treatment based on a vitamin A derivative (ATRA) and arsenic trioxide (ATO), within specific APL protocols [19,20]. Here, PML is linked to acute myeloid leukemia.